Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risedronate

K L Goa1, J A Balfour

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|July 29, 1998
PubMed
Summary
This summary is machine-generated.

Risedronate, an oral bisphosphonate, effectively reduces bone resorption and improves bone density in conditions like osteoporosis and Paget's disease. Clinical trials show it is well-tolerated with outcomes comparable to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Levetiracetam.

CNS drugs·2013
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Rheumatology

Background:

  • Risedronate is an oral pyridinyl bisphosphonate.
  • It inhibits osteoclast-mediated bone resorption.
  • It can be administered in lower dosages compared to other antiresorptive bisphosphonates.

Purpose of the Study:

  • To evaluate the efficacy of risedronate in treating bone loss and related conditions.
  • To compare risedronate with etidronate in patients with Paget's disease.
  • To assess the effect of risedronate on bone mass and bone loss prevention.

Main Methods:

  • Experimental models of osteoporosis.
  • Randomized double-blind trial in Paget's disease patients comparing risedronate and etidronate.
  • Clinical trials in postmenopausal women and rheumatoid arthritis patients on glucocorticoids.

Related Experiment Videos

Main Results:

  • Risedronate inhibited bone loss and improved trabecular architecture in experimental models.
  • In Paget's disease, risedronate (30 mg/day for <= 3 months) reduced pain and serum alkaline phosphatase.
  • Risedronate (5 mg/day for <= 2 years) increased bone mass in postmenopausal women and prevented bone loss in glucocorticoid-treated patients.

Conclusions:

  • Risedronate is effective in managing Paget's disease and preventing bone loss in postmenopausal women.
  • It demonstrates efficacy in preventing bone loss in patients on glucocorticoid therapy.
  • Adverse event profiles were similar to placebo in clinical trials.